Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Devyser Diagnostics AB's enterprise value is €97.67 Mil.
Devyser Diagnostics AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €5.12 Mil. Therefore, Devyser Diagnostics AB's EV-to-EBITDA for today is 19.09.
The historical rank and industry rank for Devyser Diagnostics AB's EV-to-EBITDA or its related term are showing as below:
FRA:OL0'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -983.59 Med: -29.3 Max: 114.29
Current: 19.22
During the past 9 years, the highest EV-to-EBITDA of Devyser Diagnostics AB was 114.29. The lowest was -983.59. And the median was -29.30.
FRA:OL0's EV-to-EBITDA is ranked worse than 63.48% of 512
companies
in the Medical Devices & Instruments industry
Industry Median: 14.645
vs FRA:OL0: 19.22
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Devyser Diagnostics AB (FRA:OL0) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Devyser Diagnostics AB's PE Ratio (TTM) for today is calculated as:
Devyser Diagnostics AB's share price for today is €5.90.
Devyser Diagnostics AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.085.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Devyser Diagnostics AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Devyser Diagnostics AB EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Devyser Diagnostics AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Devyser Diagnostics AB's EV-to-EBITDA falls into.
Devyser Diagnostics AB's current Enterprise Value is €97.67 Mil.
Devyser Diagnostics AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Devyser Diagnostics AB (FRA:OL0) has a EV-to-EBITDA of 19.09 as of Aug. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Devyser Diagnostics AB. According to the industry distribution chart, Devyser Diagnostics AB ranks #325 out of 512 companies in the Medical Devices & Instruments industry, placing it in the top 63.5%.
Is Devyser Diagnostics AB's EV-to-EBITDA too high?
Devyser Diagnostics AB's current EV-to-EBITDA is 19.09. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.65. Devyser Diagnostics AB's value of 19.09 is 30.4% above this industry median. Based on the distribution chart, Devyser Diagnostics AB ranks #325 out of 512 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Devyser Diagnostics AB has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Devyser Diagnostics AB's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Devyser Diagnostics AB ranks #325 out of 512 companies for EV-to-EBITDA. This places Devyser Diagnostics AB in the lower half of its industry. The industry median EV-to-EBITDA is 14.65. Devyser Diagnostics AB's value of 19.09 is 30.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.65, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Devyser Diagnostics AB's current EV-to-EBITDA of 19.09 is 30.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Devyser Diagnostics AB. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Devyser Diagnostics AB's current EV-to-EBITDA is 19.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devyser Diagnostics AB stock overvalued right now?
Devyser Diagnostics AB (FRA:OL0) has a current EV-to-EBITDA of 19.09. The stock's GF Value™ is €12.09, compared to a current price of €5.90 — trading 51.2% below its estimated fair value. The current EV-to-EBITDA is 19.09 and 30.4% above the Medical Devices & Instruments industry median of 14.65. Devyser Diagnostics AB's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Devyser Diagnostics AB (FRA:OL0), the current EV-to-EBITDA is 19.09 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Devyser Diagnostics AB (FRA:OL0) Overvalued in 2026?
Based on GuruFocus' analysis, Devyser Diagnostics AB stock appears to be undervalued.
The current stock price of €5.90 is trading 51.2% below its estimated GF Value™ of €12.09.
Key valuation signals for FRA:OL0:
EV-to-EBITDA: 19.09
GF Value™: €12.09 vs. price of €5.90 (51.2% below fair value)
Industry Position: 30.4% above the Medical Devices & Instruments median (#325 of 512)
No single metric tells the full story. See the FRA:OL0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Devyser Diagnostics AB is engaged in the development, manufacture, and sale of kits for genetic testing in routine diagnostic laboratories. The products are used for advanced genetic testing in the hereditary disease, oncology, and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up.
67GF Score
Get the complete analysis for FRA:OL0
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OL0 has been successfully added to your 
